Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications

@article{Karpuj2002EvidenceFA,
  title={Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications},
  author={Marcela Viviana Karpuj and Mark W. Becher and Lawrence Steinman},
  journal={Neurochemistry International},
  year={2002},
  volume={40},
  pages={31-36}
}
Transglutaminase (TGase) activity is increased in affected regions of brains from patients with Huntington's disease (HD). TGase activity is particularly elevated in the nucleus compared with the cytoplasm from these brains. Gamma-glutaminyl-lysyl cross-links have been detected in nuclear inclusions in HD brain, indicating that TGase may play a prominent role in the aggregation of huntingtin (htt). Attempts to ameliorate experimental disease, via inhibition of TGase in transgenic models of HD… Expand
Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease
TLDR
Treatment in R6/2 transgenic HD mice, using the transglutaminase inhibitor cystamine, significantly extended survival, improved body weight and motor performance, and delayed the neuropathological sequela. Expand
The multifaceted role of transglutaminase in neurodegeneration: Review article
TLDR
This review will focus on the leading hypotheses in relation to both old and new experimental results on the involvement of TGase in neurodegenerative diseases, including its role in aggregate formation. Expand
Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases
TLDR
A discussion of the effect of antibodies, caspase inhibitors, chemical inhibitors, heat-shock proteins, suppressor peptides and transglutaminase inhibitors upon aggregation and disease is presented. Expand
Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice
TLDR
The YAC128 transgenic mice express the full‐length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. Expand
Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation
TLDR
It is suggested that cystamine's neuroprotective effect in HD transgenic mice results from pleiotropic effects that include transglutaminase inhibition and antioxidant activity, and an increase in brain l‐cysteine levels could be protective in HD. Expand
Huntington's disease: an update of therapeutic strategies.
TLDR
There has been a number of therapeutic advances in the treatment of HD, such as fetal neural transplantation, RNA interference, RNAi and transglutaminase inhibitors (Tgasei). Expand
New directions in therapeutics for Huntington disease.
TLDR
A literature review aims to address the latest research on promising therapeutics based on influencing the hypothesized pathological mechanisms of Huntington disease. Expand
Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies
TLDR
Findings suggest that tTGase activity leads to α-synuclein aggregation to form Lewy bodies and perhaps contributes to neurodegeneration. Expand
Transglutaminase Cross‐Links in Intranuclear Inclusions in Huntington Disease
TLDR
The hypothesis that transglutaminase catalyzed cross-linking of mutant huntingtin is involved in the formation and/or stabilization of huntingtin protein aggregates in HD is supported. Expand
Targeting Transcriptional Dysregulation in Huntington’s Disease: Description of Therapeutic Approaches
TLDR
Microarray studies in mouse models of HD and in postmortem brain samples from HD patients report a decrease in transcriptional levels of hundreds of genes, most of them selectively expressed in the striatum, the affected brain region in HD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Tissue Transglutaminase Is Increased in Huntington's Disease Brain
TLDR
Tissue transglutaminase is elevated in HD brain and may play a role in the disease process, and quantitative analysis of immunoblots and immunohistochemical and biochemical methods clearly indicate. Expand
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
  • M. Karpuj, H. Garren, +4 authors L. Steinman
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
TGase-mediated crosslinking of htt may be involved in the formation of the nonamyloidogenic nuclear inclusions found in the HD brain, and the staining properties of nuclear in Included revealed that they were not amyloid. Expand
Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
TLDR
It is shown here that huntingtin is a substrate of transglutaminase in vitro and that the rate constant of the reaction increases with length of the polyglutamine over a range of an order of magnitude. Expand
Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo
TLDR
In this study, it is shown that the proteolytic cleavage of a GST-huntingtin fusion protein leads to the formation of insoluble high molecular weight protein aggregates only when the polyglutamine expansion is in the pathogenic range. Expand
Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3
TLDR
It is suggested that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein. Expand
Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation
TLDR
It is observed that mice transgenic for exon 1 of the human HD gene carrying CAG115 to (CAG)156 repeat expansions develop pronounced neuronal intranuclear inclusions, containing the proteins huntingtin and ubiquitin, prior to developing a neurological phenotype. Expand
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
TLDR
Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations, supporting a role of metabolic dysfunction in a transgenic mouse model of HD and suggesting a novel therapeutic strategy to slow the pathological process. Expand
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.
TLDR
An NH2-terminal fragment of mutant huntingtin was localized to neuronal intranuclear inclusions and dystrophic neurites in the HD cortex and striatum, and polyglutamine length influenced the extent of huntingtin accumulation in these structures. Expand
Amyloid-like inclusions in Huntington’s disease
TLDR
It is shown that some inclusions in Huntington's disease brain tissue possess an amyloids-like structure, suggesting parallels with other amyloid-associated diseases such as Alzheimer's and prion diseases. Expand
Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Poly‐Q Neurodegenerative Diseases?
Abstract: Huntington's disease and six other neurodegenerative diseases are associated with abnormal gene products containing expanded polyglutamine (poly‐Q; Qn) domains (n ≥ 40). In the presentExpand
...
1
2
3
...